- Home
- Blogs
Paediatric medicines in the EU, the UK and the U.S.: regulatory framework in a nutshell
Blog Post
18 October 2022
Author
Browse this blog post
Related news and insights
Blog Post: 03 April 2024
European Commission opens unprecedented abuse of dominance probe in animal medicines sector
Blog Post: 28 March 2024
Publications: 13 March 2024
Abuse of dominance enforcement declines as new forums emerge
Publications: 13 March 2024
In a recently published Practice Note commissioned by LexisPSL, our life sciences experts look at the EU and the UK regulations in paediatric medicines, interspersed with insights from a US perspective. This Practice Note thoroughly analyses the legislative framework in both the EU and UK and provides an overview of the key obligations and incentives for pharmaceutical companies that were introduced to increase the number of paediatric studies and approved paediatric drugs. As a new proposal for the EU Paediatric Regulation is expected, the authors also undertake a critical review of the efficacy of the current European framework.
For more information regarding these obligations and incentives, please find the full Practice Note on Paediatric medicines below.